The Genetics Lab You’d Build
The contract research market is changing, making it harder for anyone but the biggest CROs to compete. After enduring what one horrified market analyst called “a sharp pullback in drug development spending…and the crippling cancellations” of work already in the pipeline, the CRO market has begun what will surely be a long recovery. What is emerging is a completely different business, a partnership-based market that ties CROs together with pharma and device developers for long periods of time.
For contract research organizations, there’s less risk in those partnerships. But servicing them requires a lot more up-front investment in human and technological infrastructure. Even though CRO revenues are bending upward, that investment is depressing profits, and likely will for years to come.
There is an alternative: outsourcing the esoteric and high-complexity genetic testing that drives up capital costs.
PGXL is a CLIA certified laboratory offering assay validation, execution and reporting to meet GLP requirements. The company provides accurate, efficient, high-volume testing and highly specialized biomarker testing. And if your needs go beyond clinical services, we also provide scientific consultation, assay development, project management, investigator support, global logistics, and data management.
Fact is, only the biggest CROs can be everything to everybody. To compete, everyone else needs to find partners of their own, specialists that can add just the right capability and expertise, on demand, without capital outlay.
Talk to us. Let us help you fill in the blanks on your next research proposal, and when you land the job feel confident that our high-throughput lab will deliver the accurate, timely results you and your customers need.
If you’ve got questions, we’ll do your best to provide answers.